Adverse events in a chiropractic spinal manipulative therapy single-blinded, placebo, randomized controlled trial for migraineurs – Fulll Text Article

Musculoskeletal Science & Practice
June 2017  Volume 29, Pages 66–71
Aleksander Chaibi, PhD (student)

Highlights

  • Manual-therapy RCTs do not always report adverse events (AEs) in contrast to pharmacological RCTs.

  • This is the first prospective manual-therapy 3-armed single-blinded placebo RCT reporting all AEs for migraineurs.

  • Local tenderness, tiredness and neck pain were the most common AEs. No severe or serious AE were reported.

  • We observed fewer AEs in our study than what is reported in prophylactic migraine RCTs such as topiramate, metoprolol or candesartan.


Abstract

Background

Unlike pharmacological randomized controlled trials (RCTs), manual-therapy RCTs do not always report adverse events (AEs). The few manual-therapy RCTs that provide information on AEs are frequently without details, such as the type and-, severity of the AE and reason for withdrawal.

Objective

To prospectively report all AEs in a chiropractic spinal manipulative therapy (CSMT) RCT.

Design

A prospective 3-armed, single-blinded, placebo, RCT.

Methods

Seventy migraineurs were randomized to the CSMT or a placebo, with 12 intervention sessions over three months. The recommendations by CONSORT and the International Headache Society’s Task Force on AEs in migraine RCTs were followed. A standardized reporting scheme designed for pharmacological RCTs was used, and the AEs were described as frequencies and percentages within each group. The 95% confidence intervals (CIs) for the percentages (absolute risk) of AEs in each group were calculated when possible. Attributable risk (%) and relative risk were calculated with the corresponding 95% CIs.

Results

AEs were assessed in 703 sessions, with 355 in the CSMT group and 348 in the placebo group. Local tenderness was the most common AE, reported by 11.3% and 6.9% of the CSMT group and the placebo group, respectively, and tiredness on the intervention day was reported by 8.5% and 1.4% of CSMT group and the placebo group, respectively. The highest attributable risk was for tiredness on the treatment day, 7.0% (CI 3.9–10.2%) which presented a relative risk of 5.9 (CI 2.3–15.0).

Conclusions

AEs were mild and transient, and severe or serious AEs were not observed.

Full Text Article

Comments Are Closed